Allergan Stock Price, News & Analysis (NYSE:AGN)

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan announced a quarterly dividend on Friday, July 19th. Shareholders of record on Tuesday, August 13th will be paid a dividend of $0.74 per share on Friday, September 13th. This represents a $2.96 dividend on an annualized basis and a yield of 1.69%. The ex-dividend date of this dividend is Monday, August 12th. View Allergan's Dividend History.

Allergan announced that its Board of Directors has approved a share buyback program on Tuesday, January 29th 2019, which authorizes the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 4.1% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's management believes its stock is undervalued.

Allergan plc (NYSE:AGN) announced its earnings results on Tuesday, August, 6th. The company reported $4.38 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $4.34 by $0.04. The company earned $4.09 billion during the quarter, compared to the consensus estimate of $3.93 billion. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The company's revenue was down .8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.42 earnings per share. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Allergan.

Allergan issued an update on its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of >$16.55 for the period, compared to the Thomson Reuters consensus estimate of $16.74. The company issued revenue guidance of 15.4-15.6 billion, compared to the consensus revenue estimate of $15.32 billion.

21 analysts have issued 12-month price objectives for Allergan's stock. Their predictions range from $144.95 to $255.00. On average, they expect Allergan's stock price to reach $179.15 in the next twelve months. This suggests a possible upside of 2.5% from the stock's current price. View Analyst Price Targets for Allergan.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 15 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

News coverage about AGN stock has trended very negative this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allergan earned a daily sentiment score of -3.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the next several days. View News Stories for Allergan.

Allergan saw a increase in short interest in September. As of September 30th, there was short interest totalling 10,330,000 shares, an increase of 8.9% from the August 30th total of 9,490,000 shares. Based on an average daily volume of 3,600,000 shares, the short-interest ratio is currently 2.9 days. Approximately 3.2% of the shares of the stock are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.54%), Strs Ohio (0.20%), Calamos Advisors LLC (0.10%), Commerzbank Aktiengesellschaft FI (0.09%), Robeco Institutional Asset Management B.V. (0.06%) and Metropolis Capital Ltd (0.05%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Metropolis Capital Ltd, Envestnet Asset Management Inc., West Coast Financial LLC, Confluence Investment Management LLC, Meeder Asset Management Inc., Farmers & Merchants Investments Inc. and Nippon Life Global Investors Americas Inc.. View Insider Buying and Selling for Allergan.

AGN stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, Strs Ohio, Alpine Group USVI LLC, Alpine Group USVI LLC, Havens Advisors LLC, State of Alaska Department of Revenue and Cerebellum GP LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $174.70.

Allergan has a market capitalization of $57.32 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]